Bio-Techne licenses AI-designed proteins from Monod Bio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
November 18, 2025 6:30 AM ESTPartnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine
MINNEAPOLIS and SEATTLE, Nov. 18, 2025 /PRNewswire/ --Â Bio-Techne Corporation (NASDAQ:... More
